| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Used to treat urea cycle disorders Sodium phenylbutyrate helps remove ammonia from the body. -Phenyl-butyrate (PB)4 is an aromatic fatty acid that is converted in vivo to phenylacetate (PA) by β-oxidation in liver and kidney mitochondria. -In human body, phenylbutyrate is oxidized to phenylacetate, which is in turn conjugated with glutamine and eliminated in urine as phenylacetylglutamine, thereby mediating elimination of waste nitrogen -Phenylbutyrate is one of the first drugs encountered in cancer therapy as a histone deacetylase inhibitor (HDACI) (relatively weak compared to vorinostat (SAHA), romidepsin, etc.). -Butyric acid is one of the short-chain fatty acids produced by the gut microbiota through the fermentation of dietary fiber. Butyrate is primarily recognized for its beneficial effects in the colon and is tightly linked to gut health. -Phenylbutyrate is a derivative of butyrate that has been chemically modified by the addition of a phenyl group. This structural change increases its lipophilicity (fat solubility) and alters its metabolic fate and biological activity. This allows it to be used as a systemic drug, in contrast to the locally produced butyrate in the gut, which is rapidly metabolized by colonocytes Pathways: -Histone deacetylase (HDAC) inhibitor -ER stress inhibitor (at least in normal cell) -Can act as a chemical chaperone, helping to reduce ER stress by facilitating proper protein folding. -Modulation of NF-κB Signaling -Changes in pathways such as PI3K/Akt/mTOR and MAPK. -Some preclinical investigations have reported that treatment with phenylbutyrate leads to mitochondrial dysfunction and endoplasmic reticulum (ER) stress, both of which can result in an increase of ROS within cancer cells. Note: Sodium butyrate (NaBu) vs Sodium phenylbutyrate -Sodium butyrate is primarily a research tool with limited clinical application, whereas phenylbutyrate is used clinically -Phenylbutyrate typically exhibits improved pharmacokinetics and is more amenable to systemic use compared to sodium butyrate. -Both compounds act as HDAC inhibitors, phenylbutyrate additionally modulates ER stress and mitochondrial function, leading to potentially greater ROS production in certain cancer cells. https://www.purepba.com/shop/
|
| Source: |
| Type: |
| Chemical chaperones are small molecules that assist proteins in folding correctly, thereby reducing misfolding and aggregation. -Cancer cells often exhibit high levels of protein synthesis and stress on the protein-folding machinery (such as the endoplasmic reticulum, ER). Misfolded proteins can lead to ER stress and activate the unfolded protein response (UPR). Chemical chaperones can help alleviate this stress by assisting in proper protein folding and reducing aggregation, potentially affecting the survival and proliferation of cancer cells. -4-Phenylbutyric acid (4-PBA): One of the most extensively studied chemical chaperones, 4-PBA has been researched for its ability to reduce ER stress in various cellular models, including cancer. -Tauroursodeoxycholic acid (TUDCA): Another chemical chaperone that has been investigated for similar properties in alleviating ER stress. -Challenges: The dual role of the UPR in both cell survival and death means that the context of treatment is crucial. Moreover, systemic administration of chemical chaperones might affect normal tissues, so selectivity and dosing become important considerations. |
| 2029- | PB, | Phenylbutyric Acid: simple structure - multiple effects |
| - | Review, | Var, | NA |
| 2030- | PB, | 4-Phenylbutyric acid protects against neuronal cell death by primarily acting as a chemical chaperone rather than histone deacetylase inhibitor |
| - | Review, | Nor, | NA |
| 2031- | PB, | Phenylbutyrate is a multifaceted drug that exerts neuroprotective effects and reverses the Alzheimer´s disease-like phenotype of a commonly used mouse model |
| - | in-vivo, | AD, | NA |
| 2034- | PB, | Protective effects of 4-phenylbutyrate derivatives on the neuronal cell death and endoplasmic reticulum stress |
| - | in-vitro, | Nor, | SH-SY5Y |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:15 Target#:1230 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid